First-in-class drug for chronic cough shows efficacy
Only the higher dose gave better results than placebo in two parallel phase three trials, investigators report
AusDoc brings you the latest news from the European Respiratory Society Congress 2020.
Gefapixant, a first-in-class P2X3 receptor antagonist, is efficacious for chronic cough but only at the higher of two doses tested, trial results show.
Results of two parallel randomised industry-funded placebo-controlled trials, COUGH-1 and COUGH-2, including more than 2000 patients, were presented as at the European Respiratory Society’s 2020 (ERS 2020) virtual international congress this week.
All participants (75% female, 79% Caucasian) had suffered chronic cough that was unexplained or refractory for at least a year (mean duration was over a decade) without substantial abnormalities on chest X-ray.
